A low-profile pharma firm, Advent controlled-BSV, has drawn major investor attention after a turnaround that tripled its valuation in five years. Its focus on specialised women’s health products and a strong research pipeline have helped drive the momentum. Now, Mankind is set to acquire BSV in a $1.6 billion deal, putting the company’s next growth phase in the spotlight.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
